23 May 2013
Keywords: teva, loses, exclusivity, pravastatin, fda, israel, pharmaceuticals
Article | 18 July 2005
Israel's Teva Pharmaceuticals has received a letter from the US Food and Drug Administration casting doubt over the 180-day exclusivity ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 July 2005
11 July 2005
22 May 2013
© 2013 thepharmaletter.com